Prevalence of antimicrobial resistance among 723 outpatient clinical isolates of Moraxella catarrhalis in the United States in 1994 and 1995: results of a 30-center national surveillance study
| Autor: | H P Holley, Angela B. Brueggemann, Gary V. Doern, G Pierce, A Rauch, T Hogan |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
medicine.medical_specialty
Neisseriaceae Infections Microbial Sensitivity Tests Cefpodoxime Microbiology Moraxella catarrhalis chemistry.chemical_compound Cefprozil Internal medicine Moraxella (Branhamella) catarrhalis parasitic diseases medicine Humans Pharmacology (medical) Loracarbef Moraxella Pharmacology biology business.industry Drug Resistance Microbial biology.organism_classification United States Anti-Bacterial Agents Infectious Diseases chemistry Population Surveillance business Cefuroxime Cefixime medicine.drug Research Article |
| Zdroj: | Europe PubMed Central |
| Popis: | Seven hundred twenty-three isolates of Moraxella catarrhalis obtained from outpatients with a variety of infections in 30 medical centers in the United States between 1 November 1994 and 30 April 1995 were characterized in a central laboratory. The overall rate of beta-lactamase production was 95.3%. When the National Committee for Clinical Laboratory Standards MIC interpretive breakpoints for Haemophilus influenzae were applied, percentages of strains found to be susceptible to selected oral antimicrobial agents were as follows: azithromycin, clarithromycin, and erythromycin, 100%; tetracycline and chloramphenicol, 100%; amoxicillin-clavulanate, 100%; cefixime, 99.3%; cefpodoxime, 99.0%; cefaclor, 99.4%; loracarbef, 99.0%; cefuroxime, 98.5%; cefprozil, 94.3%; and trimethoprim-sulfamethoxazole, 93.5%. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|